Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Exploring High Growth Tech Stocks In The US Market April 2025

In This Article:

Over the last 7 days, the United States market has dropped 5.6%, yet it has risen by 3.3% over the past year, with earnings expected to grow by 14% per annum in the coming years. In this fluctuating environment, identifying high growth tech stocks requires a focus on companies that demonstrate robust innovation and adaptability to capitalize on future opportunities.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.44%

29.79%

★★★★★★

TG Therapeutics

26.03%

37.60%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Travere Therapeutics

28.45%

65.05%

★★★★★★

Clene

60.86%

63.07%

★★★★★★

AVITA Medical

27.91%

55.77%

★★★★★★

TKO Group Holdings

22.48%

25.17%

★★★★★★

Alnylam Pharmaceuticals

22.44%

58.55%

★★★★★★

Lumentum Holdings

21.61%

120.49%

★★★★★★

Ascendis Pharma

32.36%

59.79%

★★★★★★

Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Heron Therapeutics

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutics that enhance medical care, with a market capitalization of approximately $339.69 million.

Operations: Heron Therapeutics focuses on developing and commercializing therapeutic products, primarily generating revenue from its Drug Delivery Systems segment, which reported $144.29 million in revenue.

Heron Therapeutics, transitioning into profitability within the next three years, is demonstrating a robust trajectory with expected annual profit growth surpassing average market projections. Despite its current unprofitable status and a highly volatile share price, the company has significantly reduced its net loss to $13.58 million from $110.56 million year-over-year and anticipates revenue between $153 million and $163 million for 2025. This forward-looking guidance aligns with an annual revenue growth rate of 12%, outpacing the US market's average of 8.3%. Heron's strategic focus on enhancing operational efficiencies while expanding its market footprint could potentially reshape its financial landscape in the burgeoning biotech sector.

NasdaqCM:HRTX Earnings and Revenue Growth as at Apr 2025
NasdaqCM:HRTX Earnings and Revenue Growth as at Apr 2025

Canaan

Simply Wall St Growth Rating: ★★★★★☆

Overview: Canaan Inc. focuses on the research, design, and sale of integrated circuits (IC) and leases mining equipment for bitcoin mining in China, with a market cap of approximately $334.82 million.